Bionor Pharma`s Hypothesis for Immune Activation Mediated by the C5 Region of HIV Presented at Scientific Conference
Findings Provide Further Support for the Rationale Behind Bionor Pharma`s Second HIV Vaccine, Vacc-C5 (Oslo, 5 April 2013) Bionor Pharma ASA (OSE: BIONOR) today announced that their scientific work entitled “The C5 region of HIV-1 gp120 shares homology with the shared epitope of HLA-DRß1 and activates immune responses. Anti-C5 antibodies correlate with protection from HIV-1 disease …
Patent Application Submitted With Bionor Pharma`s HIV-Vaccines for Use in Combination Therapy
Oslo 26.02.2013 – The combination with complementary formulations aims to optimize future HIV treatments Bionor Pharma ASA (OSE: BIONOR) today announced that a new patent application relating to the Company`s HIV-vaccines Vacc-4x and Vacc-C5 has been submitted. The patent application contains claims covering various combinations of our vaccines with other agents such as immune modulators …
Approved “reboost” with Vacc-4x
05.12.2012 – Final Approvals Received for International Study to Reboost Patients From the Completed Vacc-4x Phase II Trial Approximately 40 Patients Will Participate at 11 Clinics in USA and Europe News Summary * Study design: Open, clinical phase II study, with two Vacc-4x immunizations while patients remain on conventional HIV medication (Antiretroviral Therapy, ART), followed …
Presentation of the scientific background and update of the business development in Bionor Pharma, Nov. 2012
The rationale behind Bionor Pharma`s HIV vaccine research is presented by Dr. Jerry Zeldis from Celgene, and Prof. Gus Dalgleish, St. George`s University of London. Update on the Company – Steen Krøyer, CEO of Bionor Pharma Background for Bionor Pharma`s research cooperation with Celgene – Dr. Jerome “Jerry” Zeldis, CEO of Celgene Global Health and Chief Medical …
Bionor Pharma presents data from HIV vaccine research at scientific meeting in Baltimore
Baltimore 14.10.2012 – Research on Vacc-4x and Vacc-C5 is today presented at the Annual Meeting of Institute of Human Virology Baltimore 14 October: Bionor Pharma (OSE: BIONOR) presents today research of the Company’s two HIV vaccines Vacc-4x and Vacc-C5, and the combination of these two vaccines at the Annual International Meeting of Institute of Human …
Study of Vacc-4x Combined with Celgene`s Revlimid® Approved to Begin
Oslo 13.08.2012 – Study of Vacc-4x Combined with Celgene`s Revlimid® (lenalidomide) in HIV Patients with Impaired Immune System Approved to Begin News Summary Placebo-controlled, double-blind clinical study combining Vacc-4x with Celgene`s Revlimid® (lenalidomide) approved to start at four clinics in Germany Study seeks to improve the immunological response in patients who have failed to recover …
Vacc-4x Improves Quality of Immune Responses in HIV Patients, Resulting in Long-Term Reduction in Viral Load
Oslo 20.07.2012 – Therapeutic HIV Vaccine Vacc-4x Improves Quality of Immune Responses in HIV Patients, Resulting in Long-Term Reduction in Viral Load and Potential for Periodic “Boosts” that Could Result in New Treatment Option for People Living with HIV/AIDS. Bionor researchers report findings at AIDS 2012 “Towards an HIV Cure” pre-conference symposium. News summary • Bionor …
HIV- and Oncology Research Expert Professor Gus Dalgleish Joins Clinical Advisory Board Bionor Pharma
Oslo, 17.07.2012. HIV- and Oncology Research Expert Professor Gus Dalgleish Joins Clinical Advisory Board Bionor Pharma. Professor Dalgleish joins growing global board to help find a cure or functional cure for HIV Bionor Pharma ASA announced today that the HIV expert from the UK based St. George’s University of London, Professor Angus “Gus” Dalgleish is …
Patent Application for Vacc-HIV, a Therapeutic and Potentially Preventive HIV Vaccine
Oslo 07.06.2012 – Vacc-HIV is a combination of Vacc-4x and Vacc-C5. The combined patent is developed for further protection of the two vaccines alone, in addition to protecting the use of these vaccines in combination Bionor Pharma ASA announced today that it has initiated the international patent process for protection of the Company`s peptide vaccine …
First Human Study of HIV Vaccine Vacc-C5 to begin
Oslo 29.05.2012 – Animal Studies Indicate Similar Generation of Immune Responses as Those in HIV Patients who Naturally Suppress the Infection News Summary Open, clinical study, dose escalating, phase I/II, with Bionor Pharma`s second therapeutic HIV vaccine to begin at Oslo University Hospital. Researchers hope Vacc-C5 will prevent hyperactivation of immune system that leads to …